上海爱科百发生物医药技术股份有限公司
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
ArkBio Initiates Phase II Clinical Trial of AK0610, a Preventive Monoclonal Antibody for Respiratory Syncytial Virus Infection 2025-10-30 09:00
ArkBio's Ziresovir Included into Pediatric RSV Drug Priority List by WHO 2025-07-16 09:00
ArkBio's New Drug Application for ADHD Therapeutic Azstarys Accepted and Granted Priority Review by China NMPA 2025-06-16 09:00
ArkBio Announces Positive Phase II Results of AK3280 for Treatment of Idiopathic Pulmonary Fibrosis (IPF) 2025-05-16 09:00
The Lancet Child & Adolescent Health Publishes Phase III Trial and 24-Month Follow-Up Results of Ziresovir for RSV in Infants Under 6 Months 2025-04-16 09:00
ArkBio Announces the Completion of Phase III Clinical Study for AK0901 in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in China 2025-03-24 09:00
ArkBio Announces Successful Completion of Enrollment and Dosing for Phase 1 Clinical Study of AK0610, a Preventive Antibody Against Respiratory Syncytial Virus Infection 2024-11-25 08:18
ArkBio Announces Publication of Phase 3 Clinical Trial Results of Ziresovir for the Treatment of RSV Infection in The New England Journal of Medicine 2024-09-26 20:28
ArkBio Presented at the 8th Annual IPF Summit and Announced Completion of Patient Enrollment for Phase 2 Clinical Trial of AK3280, a Next-Generation Drug for IPF Treatment 2024-08-27 09:00
Ark Biopharmaceutical Receives IND Approval from NMPA for AK0610, a Respiratory Syncytial Virus Neutralizing Antibody 2023-11-23 08:00
Ark Biopharmaceutical and Calibr, a Division of Scripps Research, Announce Co-development Collaboration on AK0705, a Potential First-in-Class Drug for Treating a Broad Spectrum of Respiratory Diseases, Including COPD 2023-03-16 07:50
1